Rising Preference for Generic Drug Variants to Negatively Impact Global Kidney Cancer Drugs Market

According to the latest research report released by Transparency Market Research, the global kidney cancer drugs market is expected to grow consistently at a CAGR of 6.6% during the period between 2014 and 2020. The report titled “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” forecasts that in 2013, the global kidney cancer drugs market was worth US$2.6 billion and with consistent growth, the market will be valued at US$4.5 billion by 2020.

Browse the full Kidney Cancer Drugs Market report at

http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

According to the World Cancer Research Fund International, kidney cancer is the twelfth most common cancer in the world. Also known as Renal Cell Carcinoma (RCC), it is associated with smoking, obesity, and reduced physical activity. The report mentions that the rise in the reported cases of kidney cancer worldwide along with rising geriatric population will fuel the growth of the global kidney cancer drugs market. The report cites that the growth of the global kidney cancer drugs market will get fuelled by the approval and commercialization of novel molecules in treating kidney cancer. However, the high cost of the drugs will deter the growth of the global kidney cancer drugs market. The report predicts that the increasing preference of generic drug variants will negatively impact the global kidney cancer drugs market.

The report studies the global kidney cancer drugs market depending upon the major branded drug used by the patients. Votrient, Inlyta, Avastin, Torisel, Proleukin, Afinitor, Sutent, and Nexavar are the major branded drug segments of the global kidney cancer drugs market. In 2013, Sutent dominated the global kidney cancer drugs market with more than 30% of the market share. Sunitinib (marketed as Sutent by the drug-manufacturing giant Pfizer) has been often used as the first-line treatment for renal cell carcinoma. The report suggests that the high price of the drug is expected to slow down the growth of this drug segment and the segment will reflect a sluggish growth at 1.1% from 2012 to 2016 and at 2.1% CAGR from 2016 to 2020. Votrient is predicted to be the fastest growing segment of the global kidney cancer drugs market. It is projected to take a leap at 41.7% CAGR during the period between 2012 and 2016. The growth of this segment will slow down considerably from 2016 to 2020 to a CAGR of 8.9%.

The report segments the global kidney cancer drugs market on the basis of the potential pipeline drugs to be launched during the forecast horizon. Cabozantinib, AGS-003, Dovitinib, Opdivo, and Keytruda are some of the drugs expected to be launched and commercialized during the period between 2012 and 2016, thereby strengthening the overall global kidney cancer drugs market.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/kidney-cancer-drugs-market.htm

Geographically, the report segments the global kidney cancer drugs market into four key regions: North America, Asia Pacific, Europe, and Rest of the World. North America was the largest region of the global kidney cancer drugs market, accounting for more than 45% share. Due to the U.S. being the largest pharmaceutical market worldwide, the overall cancer drugs market receives the highest revenue for each of the drug segments from the country. The U.S. accounts for more than 90% of the global kidney cancer drugs market in North America, followed by Canada, which fills up the remaining market share in the region. The report mentions that the kidney cancer drugs market in Asia Pacific region will grow at a CAGR of 6% due to the rising demand from countries such as Australia, Japan, New Zealand, and China.

The global kidney cancer drugs market is highly consolidated with GlaxoSmithKline, Novartis AG, and Pfizer Inc. being some of the key players. Pfizer dominated more than 40% of the global kidney cancer drugs market in 2013.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=537

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.